2. Importance of margin width and re-excision in breast conserving treatment of early breast cancer; a Danish Breast Cancer Cooperative Group study at 11,900 women

3. HER2 status as predictive marker for AI vs Tam benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

4. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cycliphosphamide followed by docetaxel (ACT) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients.

5. Trastuzumab emtasine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

6. Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) triall

7. NEO-EXCEL phase III neoadjuvant trial of pre-operative exemstane or letrozole +/ celecoxib in the treatment of ER positive postmenopausal early breast cancer

8. Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z—Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781)

9. HER A trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis

10. The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ o f the breast

11. Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated wth breast conserving surgery over 30 years

12. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/ Alliance/ ECOG ACRIN/ NCIC Clinical Trials Group/ NRG Oncology study S0307

Effect of regular exercise on survival in women with early stage luminal-a breast cancer

14. Short and Long-term Toxicity and Cosmesis After Interstital Multicatheter Brachytherapy for Accelerated Partial Breast Irradiation: A Multi-Institutional Study

15. 241: Impact of Ipsilateral Blood Pressure Measurements, Blood Draws, Infusions, and Air Travel on the Risk of Lymphedema forPatients Treated for Breast Cancer: A Prospective Study

16. Impact of Sequencing Radiation Therapy and Chemotherapy on Long-term Local Toxicity for Early Breast Cancer: Results of a Randomized Study at 15 Year Follow up

17. Physician-driven variation in non-recommended imaging for women with early stage breast cancer

18. Outcome analysis of patients with breast cancer and positive sentinel node

19. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin containing neoadjuvant chemotherapy in patients witt TNBC: Results from GeparSixto

20. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2 positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance)

21. NRG Oncology/ RTOG 1014: 1 Year Toxicity Report From a Phase II Study of Repeat Breast Preserving Surgery and 3-D Conformal Partial-Breast Reirradiation (PBrl) for In-Breast Recurrence

22. Concordance of local and central HER2 status in 1597 patients participating in German neoadjuvant breast cancer studiesd 3-D Conformal Partial-Breast Reirradiation (PBrl) for In-Breast Recurrence

23. PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post menopausal women with hormone receptorpositive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy

24. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance)

25. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomized trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV capecitabine (CAP) for HER2 negative locally recurrent/ metastatic breast cancer (LR/mBC)

26. Radiotherapy plus trastuzumab in the treatment of Her2 positive locally advanced breast cancer

27. “High risk permenopausal luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: results from DBCG77B randomized trial”